In Q2 2020 after enrolling about 40 patients in the Phase II clinical trial, ERC will submit its request for commercialization in the USA
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Review our Cookie and Privacy Policy for more details.